The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 02, 2025
Filed:
Dec. 21, 2021
Allogene Therapeutics, Inc., South San Francisco, CA (US);
Pfizer Inc., New York, NY (US);
Shanshan Lang, San Mateo, CA (US);
Thomas John Van Blarcom, Oakland, CA (US);
Michael Thomas Bethune, Castro Valley, CA (US);
Siler Panowski, Berkeley, CA (US);
Nguyen Tan, Berkeley, CA (US);
Yi Zhang, Foster City, CA (US);
Barbra Johnson Sasu, San Francisco, CA (US);
Zhe Li, Burlingame, CA (US);
Allogene Therapeutics, Inc., South San Francisco, CA (US);
Pfizer Inc., New York, NY (US);
Abstract
A reversibly gated effector polypeptide e.g. a chimeric antigen receptor (protease-activating CD45-gate CAR) comprising an extracellular CD45 recruiting domain, a protease-cleavable linker, and a polypeptide comprising an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain. Nucleic acids including vectors and expression vectors that encode the protease-activating CD45-gate CAR and cells including immune cells such as T cells that comprise and express the nucleic acids. Methods of treatment of various conditions including various forms of cancer comprising administering the cells including CAR T cell therapy. In some embodiments, the CD45 gate at least partially inhibits activation of the protease-activating CD45-gate CAR when the protease-activating CD45-gate CAR binds antigen. The inhibition is at least partially diminished, relieved and/or eliminated when the protease-activating CD45-gate CAR is exposed to a protease that can cleave the linker.